Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.
The study showed that Trutakna (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis in adults with primary IgA nephropathy.
The final analysis on 428 patients demonstrated a significant reduction in risk of composite kidney disease progression, true stabilization of estimated glomerular filtration rate (eGFR), and a favorable safety profile through two years.
eGFR is a calculated blood test score that shows how well the kidneys filter waste from your blood.
eGFR Stabilization and Long-Term Outcomes
At 52 weeks, the mean change in eGFR from baseline was -0.1 mL/min/1.73m² for patients receiving Trutakna, compared with -5.7 mL/min/1.73m² for placebo.
Through 104 weeks, the annualized eGFR slope was -0.6 mL/min/1.73m² per year in the Trutakna group and -5.6 mL/min/1.73m² per year for placebo.
Reduction In Kidney Disease Progression Risk
Vera also reported a 76% reduction in the risk of composite kidney disease progression events through 104 weeks. The data reported 11 events among patients receiving Trutakna compared with 38 in the placebo group.
No patients in the Trutakna group underwent dialysis for at least 30 days, received a kidney transplant, or died through 104 weeks, compared with eight patients in the placebo group.
“Prevention of kidney failure or kidney-related death is the ultimate goal. We now have evidence suggesting that TRUTAKNA may help patients avoid dialysis, transplantation, or kidney-related death over the long term,” said Richard Lafayette, principal investigator for the ORIGIN 3 trial.
VERA Price Action: Vera Therapeutics shares were up 2.09% at $34.76 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments